Drugs / CDC-9 Inactivated Rotavirus Vaccine
CDC-9 Inactivated Rotavirus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06485258 | Aug 2024 → Feb 2026 | Rotavirus infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDC-9 Inactivated Rotavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06485258 ↗ |
| Known as | CDC-9 IRV | “CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection” NCT06485258 ↗ |
| Known as | IRV | “This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series.” NCT06485258 ↗ |
| Modality | Vaccine | “This is a study of CDC-9 inactivated rotavirus vaccine (IRV)” NCT06485258 ↗ |
| Route | Intramuscular | “administered via IM injection” NCT06485258 ↗ |